文献速递心脏核医学

攻克心脏淀粉样变核素显像的致命弱点:如何减少可疑与假阳性研究

Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies.
PubMed 文献 · J Nucl Cardiol · 2023-03-01

该研究回顾性分析176例接受骨亲合放射性示踪剂显像的患者,比较仅SPECT与SPECT/CT融合技术对可疑及假阳性结果的影响。在初始仅行SPECT的78例患者中,加做SPECT/CT融合后73%病例被重新分类,全部35例可疑病例均被重新分类。结论认为加做SPECT/CT可减少假阳性或可疑研究并提高诊断准确性。

要点

  • 初始仅SPECT的78例中,加做SPECT/CT融合后73%病例被净重新分类。
  • 全部35例可疑病例经SPECT/CT融合后被重新分类为不支持34例、强烈支持1例。
  • 从一开始即采用SPECT/CT融合的98例中,作为对照重新处理时无任何病例被重新分类。

核心结论

  • 加做SPECT/CT显像可减少假阳性或可疑研究,并提高该检查的诊断准确性;使用融合技术后所有假阳性和可疑研究均被消除。

研究设计与样本

  • 回顾性、系统性分析176例患者记录,比较仅SPECT与SPECT/CT融合技术,属于为期3年的影像质量改进项目。

主要发现

  • 176例中,可疑35例(19.8%)、强烈提示32例(18.18%)、不提示109例(61.93%)。
  • 初始仅行SPECT的A组(n=78)加做SPECT/CT融合后,73%的病例被净重新分类。
  • A组中全部可疑病例(n=35)被重新分类为不提示(n=34)或强烈提示(n=1)。
  • A组中73%的强烈提示病例(n=30)被重新分类为不提示(n=22),另有8例强烈提示病例经确认真阳性;13例不提示病例在SPECT/CT融合后仍为阴性。
  • 从一开始即采用SPECT/CT融合的B组(n=98)作为对照组重新处理时,无任何病例被重新分类。

关键数值与推荐

  • SPECT/CT融合技术可提高空间分辨率,能定位心肌摄取并与血池准确鉴别,而血池是主要误差来源。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Planar and single-photon emission computed tomography (SPECT) nuclear imaging techniques with bone seeking radiotracers have been increasingly adopted for diagnosis of ATTR cardiac amyloidosis. However, inherent limitations of these techniques due to lack of anatomical landmarks have been recognized, with consequent high numbers of equivocal or false positive cases. SPECT/computed tomography (CT) fusion imaging offers a significant advantage to overcome these limitations by substantially reducing inaccurate interpretations. The authors present the results of a 3-year imaging quality improvement project that focused on reducing the high number of equivocal studies that were noted in the first two years of the amyloidosis program, comparing SPECT only to SPECT/CT fusion technique. METHODS: A retrospective, systematic analysis of 176 patient records was performed to test the premise that SPECT/CT fusion imaging has the potential to reduce equivocal and false positive results. RESULTS: Of a total of 176 patients, 35 equivocal (19.8%), 32 (18.18%) strongly suggestive, and 109 (61.93%) not suggestive cases were identified. Recognizing that this was not consistent with the international data, the authors set out on a comprehensive quality assessment project to reduce the number of equivocal and false positive cases. In patients who initially underwent SPECT only (Group A; n = 78), the addition of SPECT/CT fusion resulted in the net reclassification of 73% of cases: 100% of equivocal cases (n = 35) were reclassified to not suggestive (n = 34) or strongly suggestive (n = 1). 73% of strongly suggestive cases (n = 30) were reclassified to not suggestive (n = 22) while 8 strongly suggestive cases were confirmed as true positives. 13 not suggestive cases remained negative after SPECT/CT fusion. In cases where SPECT/CT fusion was utilized from the beginning (Group B; n = 98), there were no reclassification of any of the cases when these cases were reprocessed as a control group. CONCLUSION: Addition of SPECT/CT imaging reduces the false positive or equivocal studies and increases the diagnostic accuracy of the test. All false positive and equivocal studies were eliminated using the fusion technique. Utilizing the fusion imaging technique increases the spatial resolution, with the ability to localize myocardial uptake and accurately differentiate from blood pool, which is a major source of error.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Al Taha Z, Alibazoglu D, Sabbour H, et al. Attacking the Achilles heel of cardiac amyloid nuclear scintigraphy: How to reduce equivocal and false positive studies. J Nucl Cardiol. 2023. PMID: 36859593. doi:10.1007/s12350-023-03214-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。